Synchron's endovascular BCI bet: 10 implants, thought-controlled iPad, $200M Series D

Synchron makes Stentrode, an endovascular brain-computer interface threaded through the jugular vein to the motor cortex, letting people with paralysis control phones, tablets and computers by thought.

That a catheter-delivered stent electrode in a blood vessel over the motor cortex can record enough signal to make BCIs safe, minimally invasive and scalable.

$200M Series D announced November 2025, led by Double Point Ventures, bringing total funding to US$345M at about a US$1B valuation; Australia's National Reconstruction Fund contributed A$54M (Forbes Australia).

The BCI was developed by neurologist Thomas Oxley and biomedical engineer Nicholas Opie starting in 2011, spun out of the University of Melbourne in 2012, and moved its headquarters to Brooklyn in 2016 (Forbes Australia). First human implants followed by 2019 — about five years ahead of Neuralink's.

Synchron has implanted Stentrode in ten patients with paralysis across US and Australian trials under an FDA investigational device exemption (MacRumors; Healio). In 2024 COMMAND participant Mark first controlled an Apple Vision Pro by thought; in August 2025 Synchron showed him driving an iPad natively through Apple's BCI-HID protocol — the first public thought-controlled iPad (MacRumors). The November 2025 Series D, including A$54M from Australia's National Reconstruction Fund, funds pivotal trials, manufacturing scale-up, and a next-generation whole-brain interface promised for late 2026 (Forbes Australia; Healio).

Still live and pre-commercial: Stentrode is in FDA IDE studies with ten implants, and the Series D positions Synchron to run pivotal trials and prepare a commercial launch of its first-generation platform (Healio).

Milestone is dated and concrete: ten implants under FDA IDE and the first public thought-controlled iPad demo in August 2025.

The bet is crisp: endovascular access, not open-brain surgery, is the route to a scalable BCI — a direct contrast with Neuralink.

Verifiable coverage: Forbes Australia, Healio and MacRumors report the same funding and clinical facts.

Scale is real but honest: US$345M raised and about a US$1B valuation against a better-funded rival.

Pick the least invasive route to the outcome: Synchron's catheter implant reached humans years before Neuralink's surgical chip, on a fraction of the funding and a safer regulatory story.

As of November 2025, Synchron has ten Stentrode implants across US and Australian trials and is using its $200M Series D to run pivotal trials, scale manufacturing, build engineering teams in San Diego and AI and clinical teams in New York, and rebuild a Melbourne presence tied to the NRF investment. A next-generation, catheter-delivered whole-brain interface is promised for late 2026. No commercial product has launched yet; regulatory approval and pivotal-trial data remain the gate.